SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

$BYTE is trending as community members speculate about its connection to Elon Musk's AI initiatives, particularly as a potential companion to Grok. The coin is being touted as an AI-driven memecoin with strong community support, zero fees, and burned liquidity, driving excitement.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

SLAP is trending as community members express enthusiasm and encourage each other to maintain momentum. There's a strong sense of unity and collaborative effort, with the community rallying around the idea that "we all SLAP harder together". Bullish sentiment is fueled by the team's consistent activity and real-world partnerships.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as community members express their bullish sentiment and promote the coin's simple ticker. Conversations highlight the project's strong community and its ties to the $SOL ecosystem. The community is using the term $SLAP, alluding to slapping the ask.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the crypto community anticipates potential catalysts, including the end of a government shutdown and possible ETF approvals. Community members are actively discussing potential price movements and debating whether to buy now or wait for a dip, while also referencing positive news and developments surrounding Ripple. Despite some skepticism and volatility, there's a sense of optimism fueled by potential regulatory clarity and institutional adoption.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UNH is trending due to discussions around the potential impact of ACA negotiations and government shutdowns on the healthcare sector. Community sentiment appears bearish, with concerns about the stock's recent performance and potential negative catalysts. Some investors are speculating about Berkshire Hathaway's position, while others focus on the company's long-term prospects and potential for a rebound.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending as investors discuss its correlation to Ethereum, particularly with ETH showing signs of recovery and a potential government shutdown resolution on the horizon. Community members are weighing bullish catalysts like institutional investments from JPM and Ark Invest against concerns about potential dilution and overall market volatility. Discussions include price targets, staking plans, and the company's strategic positioning within the digital finance landscape.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as a community-driven movement focused on bringing back OG meme culture. The community emphasizes unity, persistence, and building something meaningful beyond short-term trends. Discussions revolve around its potential as a moonshot and a return to the roots of internet culture.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The "crow with knife" meme coin, $CAW, is gaining attention as its community emphasizes unity and organic growth across multiple chains. Community members highlight its deflationary tokenomics and partnerships, while inviting others to join their 'cult-like' following. The coin's presence on Solana and Base blockchains is also a key talking point.

Pump.fun

Pump.fun is trending as community members discuss its potential within the Solana ecosystem and highlight recent whale activity. Conversations revolve around price targets, support levels, and the overall bullish sentiment surrounding the token, as well as its relationship with $WAGMI and $SOL. Some users point to technical indicators suggesting a possible reversal and markup season.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending as discussions revolve around the potential impact of ACA subsidy extensions and the government shutdown, with some anticipating significant movement based on upcoming news. Community members are weighing the potential bullish or bearish implications of these factors, especially in light of recent earnings and institutional activity. Discussions also speculate about the stock's longer-term potential and upcoming earnings report.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Phase 2 trial showed 66% of patients achieved undetectable hepatitis delta virus RNA with Vir’s tobevibart-elebsiran combo, with no serious safety issues reported.</li><li>Gilead’s rival therapy bulevirtide remains the only approved hepatitis delta treatment in Europe but showed lower long-term response rates in earlier studies.</li><li>VIR trended on Stocktwits as traders highlighted strong efficacy, Gates Foundation backing, and potential for a future head-to-head Phase 3 matchup with Gilead.</li></ul>Vir Biotechnology drew heightened retail attention on Sunday after unveiling new Phase 2 data showing its tobevibart-elebsiran combination achieved high rates of undetectable hepatitis delta virus (HDV) RNA, positioning the therapy as a potential rival to Gilead Sciences’ bulevirtide, which is currently the only approved HDV treatment in Europe.<h2 class="st-heading-2">Vir’s Combination Delivers Strong 48-Week Results</h2>Vir said 66% of participants in its Phase 2 SOLSTICE trial receiving monthly doses of tobevibart and elebsiran achieved undetectable HDV RNA at Week 48, while 90% showed reductions in hepatitis B surface antigen below 10 IU/mL, a marker of suppressed viral replication. Alanine aminotransferase levels normalized in more than half of the participants.The dual regimen was well-tolerated, with no grade 3 or higher treatment-related adverse events or discontinuations. The company said results were consistent even in patients with cirrhosis and high baseline viral load.“Achieving undetectable HDV RNA is a key endpoint in clinical trials, and HDV RNA undetectability is associated with better outcomes for people living with chronic hepatitis delta,” said Tarik Asselah, of the University of Paris-Cité, who presented the data at AASLD’s The Liver Meeting in Washington, D.C.<h2 class="st-heading-2">Eclipse Registration Program Advances</h2>Vir said the combination is now being evaluated in its Eclipse global Phase 3 program, comprising three randomized, controlled trials. Eclipse-1 has completed enrollment ahead of schedule, with topline results from Eclipse-1, -2 and -3 expected in the first quarter of 2027.CEO Marianne De Backer said the new 48-week data “reinforce our confidence that a monthly dose of tobevibart and elebsiran can deliver meaningful patient benefit with convenient dosing.”According to the company, the combination offers the potential to eliminate the virus by tackling the viral lifecycle through multiple mechanisms.<h2 class="st-heading-2">Gilead’s Bulevirtide Demonstrates Durable Off-Treatment Control</h2>In May, Gilead Sciences reported final results from its pivotal Phase 3 MYR301 study showing that 36% of adults treated with bulevirtide maintained virologic suppression for almost two years after stopping therapy. Participants who remained undetectable for one year post-treatment experienced no relapses in the second year of follow-up.Among those with prolonged viral clearance at 96 weeks or later, 90% remained undetectable off-treatment.Gilead said the data underscore bulevirtide’s durability after treatment cessation and the importance of sustained viral suppression during therapy. Bulevirtide 2 mg is the only approved HDV therapy in the EEA, UK, Switzerland, and Australia and is not approved in the U.S.<h2 class="st-heading-2">Stocktwits Traders See ‘Phenomenal’ Data</h2>On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume, placing it among the top ten trending stocks on the platform.<figure class="image"><img style="aspect-ratio:968/142;" src="https://news.stocktwits-cdn.com/vir_ss_jpg_558bd7efe5.webp" alt="vir ss.jpg" width="968" height="142"><figcaption>VIR sentiment and message volume as of November 9 | Source: Stocktwits</figcaption></figure>One user noted that they were encouraged by the company’s strong trial results and high-profile early backers, including the Gates Foundation and Cathie Wood’s ARK Invest, calling the data “phenomenal” and suggesting pre-market trading could reflect the momentum.<stembedurl>https://stocktwits.com/Dunnieboy1/message/635536553</stembedurl>Another investor commented that the trial outcomes appeared “extremely strong,” adding that those who entered the stock before the weekend “may reap rewards” depending on market reaction.<stembedurl>https://stocktwits.com/TDMF123/message/635536478</stembedurl>A third user compared the 66% undetectable HDV RNA rate achieved with Vir’s monthly regimen to what they said was roughly 16% efficacy for Gilead’s bulevirtide, which requires daily injections, describing the results as “good news” ahead of eventual head-to-head Phase 3 testing.<stembedurl>https://stocktwits.com/Dunnieboy1/message/635535478</stembedurl><a href="https://stocktwits.com/symbol/VIR">Vir Biotechnology’s stock</a> has declined 30% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Vir Biotechnology logo is seen on a smartphone and a computer screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown

Phase 2 trial showed 66% of patients achieved undetectable hepatitis delta virus RNA with Vir’s tobevibart-elebsiran combo, with no serious safety issues reported.

Equity

Vir Biotechnology Announces AASLD The Liver Meeting Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Companys Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) demonstrated that participants...

Insider Selling: Vir Biotechnology (NASDAQ:VIR) EVP Sells 2,385 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) EVP Verneuil Vanina De sold 2,385 shares of the company's stock in a transaction dated Wednesday, November 5th. The shares were sold at an...

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday...

Vir Biotechnology (NASDAQ:VIR) Releases Quarterly Earnings Results, Misses Expectations By $0.47 EPS

Vir Biotechnology (NASDAQ:VIR - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of...

Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates

Vir Biotechnology (VIR) delivered earnings and revenue surprises of -67.14% and -96.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View

GSK's Q3 earnings and revenue beat expectations, powered by HIV and oncology growth, prompting the company to lift its 2025 outlook.

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025

Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2025, on November 5...

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in Part 3 of the Companys Phase 1 clinical trial evaluating VIR-5500 in combination with androgen receptor...

Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains?

Vir Biotechnology (VIR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

Current Price	$5.23
Prev Close	$5.12
Open	$5.11
Dividend Yield	0.00%
50-Day Moving Average	$5.54
Beta	1.49
Avg. Volume	1.5M
PE Ratio	-1.42

52-Week High	$14.45
52-Week Low	$4.16
Market Capitalization	$712.64M
EPS (Annual)	-$3.83
Price to Book	0.90
Revenue Per Employee	$181,875.00
Enterprise Value/EBITDA	N/A

VIR
Vir Biotechnology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VIR News

VIRVir Biotechnology Inc